ArticleCommunications biology2020
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.
Open access · goldAbstract read
In one paragraph
Article in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- Vitamin C boosts DNA demethylation in TET2 germline mutation carriers.Clinical epigenetics · 2023Trial
- Embryo vitrification disturbs the pre-implantation DNA demethylation process and affects hepatic functions to threaten long-term metabolic health in mice.Journal of advanced research · 2026Article
- Astrocyte redox imbalance underlies prelimbic neuronal hypoactivity and maladaptive affective behaviors in epilepsy.Science advances · 2026Article
- Beyond redox: vitamin C in signaling, epigenetic regulation and protein modification-relevance to cancer therapy.Clinical epigenetics · 2026Review
- Clonal haematopoiesis and cardiovascular disease, defining risk, filling gaps, and framing the future.NPJ cardiovascular health · 2026Review
- Leveraging Dietary Interventions to Benefit Patients with Hematologic Malignancies and Clonal Hematopoiesis.Nutrients · 2026Review
- Novel and emerging therapeutic strategies for clonal hematopoiesis.Haematologica · 2026Review
- High-dose vitamin C: A promising anti-tumor agent, insight from mechanisms, clinical research, and challenges.Genes & diseases · 2026Review
- TET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cells.Cancer drug resistance (Alhambra, Calif.) · 2026Article
- Loss of TET2 activity limits the ability of vitamin C to activate DNA demethylation in human HAP1 cells.Epigenetics & chromatin · 2025Article
- Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia.Current hematologic malignancy reports · 2025Review
- Phytochemical profiling, antioxidant properties, and anticancer activity of Pourouma cecropiifolia Mart. from the Ecuadorian Amazon.NPJ science of food · 2025Article
- Ten-Eleven Translocation Family Proteins: Structure, Biological Functions, Diseases, and Targeted Therapy.MedComm · 2025Review
- The physiological functions of ascorbate in the development of cancer.Disease models & mechanisms · 2025Review
- Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.Haematologica · 2025Review
- TET2 promotes tumor antigen presentation and T cell IFN-γ, which is enhanced by vitamin C.JCI insight · 2024Article
- TET2 mutation in acute myeloid leukemia: biology, clinical significance, and therapeutic insights.Clinical epigenetics · 2024Review
- The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Using NMR to Monitor TET-Dependent Methylcytosine Dioxygenase Activity and Regulation.ACS chemical biology · 2024Article
- TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway.BMC cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 3 countries.
Yihong GuanDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-8002-5141
Edward F GreenbergDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Metis HasipekDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Shi ChenDepartment of Cell System & Anatomy, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA.
Xiaochen LiuDepartment of Cell System & Anatomy, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA.
Cassandra M KerrDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Daniel GackowskiDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-095, Bydgoszcz, Poland.ORCID http://orcid.org/0000-0002-7259-1511
Ewelina ZarakowskaDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-095, Bydgoszcz, Poland.
Tomas RadivoyevitchDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-9701-1851
Xiaorong GuDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Belinda WillardProteomics and Metabolomics Core, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Hideki MakishimaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-5983-8578
Aziz NazhaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Mridul MukherjiUMKC School of Pharmacy, Kansas City, MO, USA.
Mikkael A SekeresLeukemia Program, Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Yogen SaunthararajahDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0002-9757-1031
Ryszard OlińskiDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-095, Bydgoszcz, Poland.
Mingjiang XuDepartment of Cell System & Anatomy, University of Texas Health at San Antonio, San Antonio, TX, 78229, USA.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. maciejj@ccf.org.
Babal K JhaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. jhab@ccf.org.ORCID http://orcid.org/0000-0002-7660-5255
Cleveland Clinic · USNicolaus Copernicus University · PLUniversity of Miami · USCleveland Clinic Lerner College of Medicine · USThe University of Texas Health Science Center at San Antonio · USUniversity of Missouri–Kansas City · US
Funding
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MTherapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7MNovel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4MRoles of TET2-dependent DNA demethylation intermediates in hematological malignanciesR01HL145883 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI XU, MINGJIANG, YANG, FENG-CHUN · 2019 to 2022
$2.2MRole of TET2 in normal hematopoiesis and pathogenesis of myeloid malignanciesR01HL112294 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, MINGJIANG · 2012 to 2016
$1.9MTET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesisR01HL146664 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WANG, JIANLONG, XU, MINGJIANG · 2019 to 2022
$1.7MHigh-End Instrumentation (HEI) Grant Program (S10)S10OD023436 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLARD, BELINDA BELLE · 2017 to 2017
$873kBLRD VA IK2 BX001820NCI NIH HHS K12 CA076917NHLBI NIH HHS R01 HL112294NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R01 HL145883NHLBI NIH HHS R01 HL146664NHLBI NIH HHS R35 HL135795NIH HHS S10 OD023436
Abstract
Loss-of-function TET2 mutations (TET2
Indexed as
AcetylationAdministration, OralAnimalsAscorbic AcidCell ProliferationDioxygenasesDNA-Binding ProteinsHEK293 CellsHumansK562 CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLysineMiceMutationProto-Oncogene ProteinsAscorbic AcidDioxygenasesDNA-Binding ProteinsLysineProto-Oncogene ProteinsTet2 protein, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.